{"entity":{"id":"vion-pharmaceuticals","kind":"company","name":"Vion Pharmaceuticals","aka":["Vion Pharmaceuticals, Inc.","Vion"],"tldr":"Vion was a Yale spin-out whose alkylating agent laromustine reached phase 3 in older patients with acute myeloid leukaemia but was not approved; the company filed for bankruptcy in 2009.","summary":"Vion Pharmaceuticals, founded in 1992 in New Haven, Connecticut, from Yale University research, developed laromustine (Onrigin), a sulfonylhydrazine alkylating agent, for acute myeloid leukaemia in patients unfit for intensive chemotherapy. The FDA declined approval without a randomised trial and Vion filed for Chapter 11 bankruptcy in 2009. Its trials remain on ClinicalTrials.gov under Vion as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.vionpharm.com"},{"label":"ClinicalTrials.gov: trials led by Vion Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Vion%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q7933401"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New Haven, CT","country":"US","companyType":"biotech","website":"http://www.vionpharm.com","founded":1992,"stage":"defunct","investors":[],"funding":[]},"route":"/companies/vion-pharmaceuticals/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}]}}